We are excited to announce that Eagle IP has been named as the winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026.

The LSPN Awards recognize outstanding achievement, innovation, and leadership within the life sciences intellectual property community. The Cross-Border Collaboration Partner of the Year Award honors the non-US law firm that has demonstrated exceptional partnership with US law firms and life sciences companies through superior cross-jurisdictional expertise, strategic counsel, and seamless collaboration.

This award underscores the strength of our team’s commitment to delivering sophisticated, high-quality intellectual property services that effectively bridge Greater China and global markets. We remain dedicated to serving as a trusted partner to our US and international colleagues in advancing life sciences innovation through strategic patent protection and portfolio management.

Our President and Managing Director Ms. Jennifer Che traveled to Boston last week to accept the award on behalf of our entire team, as well as to speak at the LSPN two-day conference which preceded the awards ceremony.

We are truly honored to be named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026! This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration.


Explore the full list of winners from this year’s LSPN Awards USA: https://awards.newton.media/lspnawards2026/en/page/2026-winners

我们的过去活动

Recommended Insights

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

2020年10月28日
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

2026年2月27日
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

Foreign companies transferring IP out of China: things to know

2018年10月25日
Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]
Top crossarrow-right